Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer

Bull Cancer. 1989;76(4):403-6.

Abstract

Sixteen evaluable patients with non anaplastic thyroid carcinoma were treated with mitoxantrone (16 mg/m2). There was only one brief partial remission (6.3%). There was noticeable toxicity. Mitoxantrone as given in this study was not effective for this patient population.

MeSH terms

  • Adult
  • Aged
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mitoxantrone / adverse effects
  • Mitoxantrone / therapeutic use*
  • Neoplasm Metastasis
  • Thyroid Neoplasms / drug therapy*

Substances

  • Mitoxantrone